Search for: "Teva Pharmaceuticals"
Results 961 - 980
of 1,430
Sorted by Relevance
|
Sort by Date
5 Jul 2018, 8:00 am
” On a summary judgment motion by Teva, the U.S. [read post]
5 Jul 2018, 8:00 am
” On a summary judgment motion by Teva, the U.S. [read post]
6 Jan 2010, 3:32 am
’ (The SPC Blog) India: Reviewing the Indian Patent Regime after 5 years of the introduction of the pharmaceutical product patent regime (Spicy IP) UK: Department of Health proposing generic prescription drugs option (GenericsWeb) US: 7th Circuit: Enforcing contracts between joint owners: Wisconsin Alumni Research Foundation (WARF) v. [read post]
19 Aug 2011, 9:23 am
Teva Pharmaceuticals argued that the patent was invalid because anyone well-versed in the art of drug making would have known, from prior research, that sildenafil could be effective as an ED treatment. [read post]
24 Mar 2014, 10:39 am
., Androderm Endo Pharmaceuticals, Fortesta Testosterone Gel Auxilium Pharmaceuticals, Inc., Testim Testosterone Gel BioSante/Teva, Bio-T-Gel [read post]
16 Oct 2007, 2:19 am
Court of Appeal (Civil Division) Austin & Anor v Commissioner of Police of the Metropolis [2007] EWCA Civ 989 (15 October 2007) L’Oreal SA & Ors v Bellure NV & Ors [2007] EWCA Civ 968 (10 October 2007) Holmes-Moorhouse v London Borough of Richmond-Upon-Thames [2007] EWCA Civ 970 (10 October 2007) Procter & Gamble Company v Reckitt Benckiser (UK) Ltd [2007] EWCA Civ 936 (10 October 2007) Charman v Orion Group Publishing Group Ltd & Ors [2007] EWCA… [read post]
21 Aug 2008, 9:43 pm
Following the Federal Circuit's decision in Teva Pharmaceuticals USA, Inc. v. [read post]
29 Oct 2010, 4:32 pm
9/15/2010 Unlawful marketing - Levothroid and promoting Celexa and Lexapro for pediatric use Elan Corporation - $203.5 M - 7/15/2010 - improper marketing of Zonegran Teva Pharmaceuticals - $169 M - 7/26/2010 - Inflated prices reported to Medicaid WellCare Health Plans - $137.5 M- 8/9/2010 - Defrauded Medicare and Medicaid programs in several… [read post]
2 Sep 2009, 2:23 pm
Teva Pharmaceutical Industries Ltd. v. [read post]
11 May 2023, 1:16 pm
New Relists Teva Pharmaceuticals USA, Inc. v. [read post]
20 Sep 2011, 6:35 am
Teva Pharmaceuticals USA, Inc., 2011 WL 4025734 (S.D. [read post]
13 Apr 2011, 5:13 pm
Ortho-McNeil-Janssen Pharmaceuticals, Inc., No. 2-10-cv-00836 (E.D. [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) – Antitrust,… [read post]
18 Oct 2007, 11:00 pm
Quite right, said the CFI, dismissing Intervideo's appeal - CFI decision in Case T-105/06 Intervideo v OHIM, (IPKat)EPO adds EPC post-grant data to PRS database (EPO), EU Patent Jurisdiction: Details of New Proposals From Portuguese EU Presidency (Blog@IPR::JUR), (IAM), Teva invalidates acid metabolite patents for terfenedine, (Teva Pharmaceutical Industries Ltd and another v Merrell Pharmaceuticals Inc, Aventis and Sepracor [2007] EWHC 2276 (Ch) ), (IPKat),… [read post]
11 May 2011, 4:54 am
ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O) US: FDA gets the ball rolling on biosimilar/interchangeable biological product user fee program; proposal gives a hat tip to PDUFA while acknowledging the nascent state of the industry (FDA Law Blog) (Patent Docs) Products Citalopram – UK Patents Court disapproving of EPO’s approach to assessment of novelty: Lundbeck v… [read post]
6 Apr 2011, 12:18 am
Highlights this week included: India firm on ‘NO’ to data exclusivity (SiNApSE) (Generic Pharmaceuticals and IP) (Spicy IP) (Spicy IP) US: CAFC hears oral arguments on patentability of DNA claims: American Molecular Pathology, et. al, v. [read post]
7 Mar 2018, 11:52 am
Teva Pharmaceuticals USA, Inc. [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty:… [read post]
12 Aug 2009, 3:03 am
A very recent example of this type of suit is the lawsuit filed on August 5, 2009 – the day before the Northern Trust dismissal – in the Southern District of New York, by Teva Pharmaceutical Industries and affiliated companies against Merrill Lynch and related entities. [read post]
28 Aug 2019, 9:20 am
Certain defendants (namely, Purdue and Teva) chose to settle rather than roll the dice at trial. [read post]
